[{"symbol": "XDNA", "assetClass": "Equity", "aum": 2586186, "avgVolume": 5044, "cusip": "46437W105", "description": "The adviser employs a \u201cpassive management\u201d investment approach designed to track the total return performance of the index. The index is a rules-based index that consists of the stocks or corresponding depositary receipts of companies engaged in the creation, development, production, operation, provision, distribution, ownership, servicing, licensing, leasing or franchising of at least one of the DNA Modification Technology Business. The fund invests at least 80% of its net assets in DNA Modification Technology Companies. It is non-diversified.", "domicile": "US", "etfCompany": "KellyETFs", "expenseRatio": 0.78, "inceptionDate": "2022-01-13", "isin": "CA46437W1059", "name": "Kelly CRISPR & Gene Editing Technology ETF", "nav": 7.38, "navCurrency": "USD", "sectorsList": [{"industry": "Basic Materials", "exposure": 0}, {"industry": "Communication Services", "exposure": 0}, {"industry": "Consumer Cyclical", "exposure": 0}, {"industry": "Consumer Defensive", "exposure": 0}, {"industry": "Energy", "exposure": 0}, {"industry": "Financial Services", "exposure": 0}, {"industry": "Healthcare", "exposure": 100}, {"industry": "Industrials", "exposure": 0}, {"industry": "Real Estate", "exposure": 0}, {"industry": "Technology", "exposure": 0}, {"industry": "Utilities", "exposure": 0}], "website": "https://kellyintel.com/xdna/", "holdingsCount": 1}]